Brokerage firm Deutsche Bank Upgrades its rating on Novo Nordisk A/S (ADR)(NYSE:NVO). The shares have been rated Buy. Previously, the analysts had a Hold rating on the shares. The rating by Deutsche Bank was issued on Sep 12, 2016.
In a different note, On Sep 9, 2016, JP Morgan said it Downgrades its rating on Novo Nordisk A/S (ADR). The shares have been rated ‘Neutral’ by the firm. On Aug 31, 2016, HSBC said it Upgrades its rating on Novo Nordisk A/S (ADR). The shares have been rated ‘Hold’ by the firm. On Aug 8, 2016, Bank of America said it Downgrades its rating on Novo Nordisk A/S (ADR). The shares have been rated ‘Neutral’ by the firm.
Novo Nordisk A/S (ADR) (NVO) made into the market gainers list on Tuesdays trading session with the shares advancing 1.09% or 0.5 points. Due to strong positive momentum, the stock ended at $46.23, which is also near the day’s high of $46.41. The stock began the session at $46.31 and the volume stood at 31,58,295 shares. The 52-week high of the shares is $59 and the 52 week low is $44.04. The company has a current market capitalization of $120,198 M and it has 2,60,00,00,000 shares in outstanding.
Novo Nordisk A/S (ADR)(NVO) last announced its earnings results on Aug 5, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $4.17B. Analysts had an estimated revenue of $4.24B. Earnings per share were $0.59. Analysts had estimated an EPS of $0.58.
Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery development manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Company’s diabetes care segment covers insulins GLP-1 other protein-related products (such as glucagon protein-related delivery systems and needles) oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark and internationally in the United States France China and Brazil.